CORDIS
EU research results

CORDIS

English EN
Inflection Bioscience unique dual mechanism, small molecule, orally available therapeutic targeting major unmet medical needs in breast cancer

Inflection Bioscience unique dual mechanism, small molecule, orally available therapeutic targeting major unmet medical needs in breast cancer

Objective

Breast cancer is already a leading cause of death among women and most common form of cancer among European women with almost 500,000 cases in 2012 and over 1.7 million new cases globally. However, despite good progress in treatment options over the past decade, including some progress with immunotherapies, the war is far from won, with over 20% not responding to current standard care, and with the incidence of breast cancer set to rise by a massive 50% by 2030. There is now an urgent need for new effective, safe and life extending therapeutics for those women suffering and dying with breast cancer. IBL-302 is a first-in-class small molecule targeted breast cancer therapeutic that targets both the PI3K and PIM pathways. It is an
orally bioavailable pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. As the PI3K pathway is one of the most
commonly mutated pathways, this multi-path action effect closes down the main route of mutation and a primary backup PIM
pathway. This confers the promise of much greater rates of efficacy and potential utility to combat the breast cancer epidemic.
Inhibition of the PI3K pathway alone is cytostatic, it pauses cell growth but does not kill cancer cells. This has the effect of
the PIM pathways then being activated as a backup mutation pathway, allowing the cancer to progress once more. Adding
PIM inhibition on top of the PI3K inhibition actually induces apoptosis, the death of cancer cells instead of simply stalling
their growth.
A development partnership will be sought with a large pharmaceutical company to complete final stages of clinical
development required for market approval. The partner will also be responsible for the manufacture and distribution IBL-302
on an exclusive licence.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INFLECTION BIOSCIENCES LIMITED

Address

Suite 15, Anglesea House, Carysfort Avenue
A94y R59 Blackrock Dublin

Ireland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 868712

Status

Ongoing project

  • Start date

    1 June 2019

  • End date

    30 September 2019

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

INFLECTION BIOSCIENCES LIMITED

Ireland